Engflag

Alopexy

Quick links to important sections

Alopexy

Selected form

Alopexy_RU

Method of action: Alopecia Agent, Cardiac Therapy, Other Dermatological Preparations, Promoting Hair Growth, Stimulating Hair Growth

Treatment option: Alopecia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alopexy

Property Description
Active Ingredient Minoxidil
Form Cutaneous Solution (Topical Solution)
Pharmacological Class Hair Growth Stimulant, Peripheral Vasodilator
General Purpose Stabilization of hair loss in common baldness
Origin Synthetic Compound

What Type of Medicine is Alopexy?

Alopexy is a commercially recognized, synthetic dermatological preparation formulated as a hair growth stimulant for external use. Its single active ingredient is Minoxidil, a compound originally utilized as an oral antihypertensive agent. The compound's action is rooted in its original pharmacological classification as a peripheral vasodilator, a property that is clinically recognized as the basis for its local effect upon application to the scalp. Minoxidil is an established agent for the topical treatment of androgenetic alopecia, establishing the product's core identity as a non-systemic agent focused on local physiological changes in the scalp.

Composition and Pharmaceutical Form

The product is uniquely characterized by its presentation as a cutaneous solution, or liquid formulation, intended exclusively for topical administration onto the scalp. Alopexy is a single-ingredient formulation where Minoxidil is dissolved in a specific base, typically a hydroalcoholic solution. This specific solution base, which often contains propylene glycol, acts as the essential vehicle to facilitate the effective penetration of the active substance through the skin barrier to the hair follicles below the surface. The cutaneous solution is the physical form for treating hair loss in adults, confirming its presentation for practical use.

The General Purpose of Alopexy

The overarching purpose of the Alopexy formulation is to pharmacologically support and stabilize the progressive thinning associated with common baldness in appropriate adult patient groups. By delivering Minoxidil topically, the preparation is designed to exert a direct, trophic effect on the hair follicles, promote the transition of resting follicles into the active growth phase, and enhance local microcirculation. These combined physiological influences are intended to aid in the maintenance of existing hair and encourage the growth of new, thicker hair in affected scalp regions, offering a typical, focused application for patients concerned about pattern hair loss.

Regulatory References

  1. Minoxidil - StatPearls - NCBI Bookshelf
  2. DrugBank Minoxidil Monograph
  3. Minoxidil Xiromed Public Assessment Report (via EU National Register)
  4. Minoxidil 5% SmPC (via UK Register)

What side effects are possible with Alopexy?

Possible Side Effects and Safety Information

The safety profile of Alopexy (Minoxidil topical solution) is documented in official regulatory labeling, focusing on both local application site reactions and potential systemic effects from drug absorption. Adverse reactions are classified by frequency and grouped into System-Organ-Classes (SOC).

Frequency-Classified Adverse Reactions

The following summary reflects frequency classifications found in regulatory documents:

Classification Key Examples (SOC)
Very Common (ge 1/10) Headache (Nervous System)
Common (ge 1/100 to < 1/10) Hypertrichosis, Pruritus, Dermatitis, Rash (Skin); Peripheral Oedema (General)
Uncommon/Rare Dizziness, Nausea (Gastrointestinal/Nervous System); Chest Pain, Tachycardia, Palpitations (Cardiac)
Frequency Not Known Hypotension, Angioedema, Application site reactions, Temporary hair loss

Documented Safety Patterns and Constraints

The official labeling outlines specific safety considerations and patterns related to use:

  • Systemic Absorption Risk: Although topical, systemic absorption can occur, leading to the risk of Hypotension, Tachycardia, and Chest Pain, which are documented as more serious adverse reactions.
  • Population Restrictions: The 5% concentration is not recommended for women due to an increased risk of hypertrichosis (unwanted non-scalp hair growth). Safety and efficacy have not been established for individuals under 18 or over 65 years of age.
  • Time-Related Effect: A temporary increase in hair loss, known as shedding, may be observed at the start of treatment, typically occurring two to six weeks after initiation, as part of the intended physiological action.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Alopexy

Overdose scope

Feature Official Regulatory Statement
Documented overdose presentations Hypotension, Tachycardia, Palpitations, Chest Pain, Dizziness, Faintness, Headache, Nausea, Vomiting, Edema (swelling), and Sudden Unexplained Weight Gain.
Physiological systems affected (as stated in label) Cardiovascular System, Central Nervous System, Fluid and Electrolyte Balance (Sodium and Water Retention).
Dose-related or exposure-related factors (if applicable) Systemic toxicity is linked to accidental ingestion of the solution or excessive application, which increases absorption.
Population-specific overdose notes (if applicable) The product must be kept out of the reach of children, as accidental ingestion has the potential of producing serious cardiac adverse reactions.
Emergency-response statements (as written in official documents) Treatment of overdosage must be symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention if the medication is swallowed. Stop using and consult a doctor if chest pain, rapid heartbeat, faintness, dizziness, or sudden unexplained weight gain occurs.

Overdose classifications (high-level)

Classification Aspect Official Regulatory Statement
Severity classification (as defined in official documents) Potential for Serious Cardiac Adverse Events and Systemic Toxicity.
Regulatory basis (EMA / FDA / etc.) Based on official Prescribing Information and Summary of Product Characteristics.
Overdose-context constraints (as defined in official documents) No specific antidote is known.

Resulting overdose structure

Official overdose statements:

  • Overdose manifestations reflect systemic absorption, primarily presenting as cardiovascular effects (e.g., hypotension, tachycardia, chest pain) and fluid retention (e.g., edema, sudden weight gain).
  • Immediate medical attention is required upon accidental ingestion or if systemic symptoms such as faintness, dizziness, or rapid heartbeat are experienced.
  • Management for overdosage is symptomatic and supportive, and may include diuretic therapy or intravenous sodium chloride to counteract systemic effects.
  • The product label warns of the risk of serious cardiac adverse events following accidental ingestion by children.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile based on the systemic absorption of the active ingredient, listing hypotension and tachycardia as key documented presentations. The official guidance on seeking emergency help is triggered by the occurrence of these specific systemic manifestations or by accidental ingestion. Since no specific antidote is known, regulatory authorities mandate that the treatment provided must be strictly symptomatic and supportive.

Therapeutic Uses of Alopexy

What Alopexy Treats: Main Uses and Benefits

Therapeutic Focus and Patient Benefits

The primary therapeutic function of Alopexy is the management of conditions characterized by progressive and hereditary hair loss, applied across domains where additional symptomatic support is needed. This indication is specifically aligned with the clinical management of pattern hair loss.

Alopexy is commonly used to help address the symptom clusters of gradual hair loss and hair miniaturization associated with the chronic condition androgenetic alopecia (pattern baldness) in adult men and women. The medication may assist with actively supporting new hair growth in affected areas, particularly the crown of the scalp, contributing to the goal of hair density and may assist with the appearance of thicker hair strands. The primary purpose is to support the stabilization of the inherited condition and assists with supporting existing hair coverage, a context where continuous support is needed for conditions involving recurrent manifestations.

Quick Fact: Relevant for Progressive Hair Thinning

Alopexy is considered relevant in the long-term context of care to assist with supporting stability against the chronic symptoms of pattern hair loss. The long-term therapeutic context is relevant for patients coping more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

The official eligibility profile for Alopexy (Minoxidil topical solution) is defined by regulatory documents, allowing its use primarily in a specific population for hereditary hair loss and establishing absolute prohibitions based on health status and age.

Eligibility Classification Description / Status
Populations Allowed Adult men between 18 and 65 years of age with moderate androgenetic alopecia.
Populations Not Recommended Children and adolescents under 18 years and adults over 65 years (safety/effectiveness not established).
Contraindicated Populations Women (especially for the 5% formulation), individuals with known hypersensitivity to Minoxidil or excipients, and users with treated or untreated hypertension.

Condition-Based Restrictions

Use is prohibited for individuals presenting certain local or systemic health conditions:

  • Scalp Health: Contraindicated on an inflamed, irritated, infected, painful, or sunburnt scalp. This restriction is due to the potential for increased systemic absorption.
  • Hair Loss Type: Must not be used for hair loss that is sudden and/or patchy, associated with childbirth, or where the cause is unknown.
  • Cardiac Status: Individuals with known cardiovascular disease or cardiac arrhythmia must consult a physician before use.

Pregnancy and Lactation Status

Official labeling states that use is not recommended or contraindicated during both pregnancy and breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Alopexy is defined by the potential for increased systemic exposure and additive pharmacological effects. Topical Minoxidil is strictly restricted from co-administration with other external preparations on the same area of the scalp.

Topical Exposure Enhancement

Co-administration with other topical dermatological preparations is prohibited, as they may enhance the percutaneous absorption of Minoxidil through the skin barrier. Official regulatory documents explicitly restrict the simultaneous use of agents such as Topical Corticosteroids, Topical Retinoids, and Petrolatum. Combining Alopexy with these substances increases the amount of Minoxidil entering the systemic circulation, elevating the risk of adverse effects.

Systemic Pharmacodynamic Risk

If systemic absorption occurs, there is a theoretical potential for a pharmacodynamic interaction with co-administered systemic medications. Specifically, official warnings cite a risk of additive hypotensive effects when Alopexy is used by individuals taking Systemic Vasodilators or other Antihypertensive Agents. This potential for systemic interaction is officially noted as being more significant in patients with pre-existing cardiovascular dysfunction.

Formulation Safety Restriction

The product's formulation contains an ethanol base, which carries a mandatory product-substance safety restriction: Alopexy is flammable and must be kept strictly separate from sources of ignition, fire, or flame during and immediately following application.

Mechanism of Action

Alopexy functions as an agonist of the ATP-sensitive potassium channels (KATP) expressed on vascular smooth muscle cells. Binding to these channels induces their opening, resulting in the efflux of potassium ions (K^+) from the cell and subsequent hyperpolarization of the cell membrane. This change in membrane potential leads to the inactivation of voltage-gated calcium channels, promoting a reduction in intracellular calcium concentration. The net effect is the relaxation of the vascular smooth muscle, resulting in vasodilation and a subsequent increase in cutaneous blood flow around the hair follicle bulb. The compound also modulates the hair growth cycle. It acts by extending the duration of the anagen phase and delaying the initiation of the catagen phase transition. Furthermore, it has been shown to promote cell proliferation within the dermal papilla of the hair follicle.

Dosage and Administration Information

Instruction Map: How to use Alopexy — Official Administration Guidelines

This section outlines the guidelines for the topical use of Alopexy (Minoxidil cutaneous solution 5%), detailing the standardized regimen.

Administration Scope

Field Guidelines
Route of administration Topical (Cutaneous) only, applied directly to the affected area of the scalp.
Dosing schedule A fixed volume of 1 mL of the 5% solution is applied per dose. The maximum total quantity applied over a 24-hour period must not exceed 2 mL.
Age-group administration rules Use is not recommended for individuals under 18 years of age or over 65 years of age, as safety and efficacy have not been established in these groups.
Missed-dose rules If an application is missed, the user is directed to resume the regular schedule. The labeled quantity must not be doubled to compensate for the skipped dose.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type Topical (external use only).
Frequency pattern Twice daily (BID), typically morning and evening, with a minimum interval of 12 hours between applications.
Use-context constraints Use must be continuous and long-term. Application must occur on a completely dry scalp, and precautions are required to allow the solution 2 to 4 hours to dry before bedtime.

Connection to the Overall Use Protocol

The instructions establish a fixed, non-adjustable therapeutic regimen that relies on consistent twice-daily application of a precisely measured dose. The requirement for continuous use over several months confirms that the medicine is structured as a sustained, chronic therapy, which must be adhered to to maintain any outcome.

Recent Clinical Evidence

Research Evidence for Androgenetic Alopecia (Pattern Baldness)

The clinical research base for Alopexy (topical Minoxidil) was evaluated in numerous Randomized Controlled Trials (RCTs) and systematic reviews. These short- and intermediate-term RCTs were used to evaluate the measurements of topical Minoxidil when applied to the scalp of adults experiencing common pattern baldness. In these trials, patients was evaluated in comparison to a non-active solution, known as a vehicle or placebo, or to different concentrations of the active ingredient itself (such as 5% versus 2%).

Research examined outcomes monitoring physiological strain or stress related to hair follicle activity. The studies monitored measurements such as the change from baseline in the count of non-vellus (terminal) hairs within a defined target area, usually the crown or vertex of the scalp. Findings describe data show patterns related to measured hair counts in the defined target areas that were not identical to the measurements observed in the placebo groups over the study period. The body of evidence is characterized by RCTs and subsequent systematic reviews and meta-analyses that report consistent data patterns across multiple trials.

Long-Term Evidence and Durability of Follow-Up

The majority of pivotal studies exploring the measurements of topical Minoxidil was observed in defined time intervals, most often 16 weeks to 48 weeks (about one year). Longitudinal research that monitors patients for periods exceeding one year or two years is more limited. This means that long-term effects are not fully established. Research provides context but not individual predictions of long-term outcomes, and there is limited information for long-term outcomes sufficient to describe the durability of the measured patterns over multiple years.

Evidence Gaps and Research Uncertainties

Despite the consistent findings described in the short- to intermediate-term research, several limitations and uncertainties are noted in the scientific literature. The pivotal studies often monitored changes only in the vertex (crown) of the scalp, which means comparative evidence is lacking regarding the measurements or observed patterns in other balding regions. Additionally, the follow-up durations were limited in many studies. Data for certain groups remain insufficient, for instance, for older adults or patients with other significant or chronic medical conditions that were typically excluded from the primary RCTs.

Key Studies & References

  1. Public Assessment Report National Procedure Minoxidil 5% cutaneous solution (minoxidil) (Regulatory Efficacy/Safety Overview)
  2. Minoxidil Xiromed 20 mg/ml and 50 mg/ml cutaneous solution - Public Assessment Report Scientific discussion (EU Monograph)

Frequently Asked Questions (FAQ)

Common questions about Alopexy (FAQ)

Q: What is Alopexy used for?

A: Alopexy is a topical solution that contains minoxidil. It is indicated for the treatment of hereditary hair loss (androgenetic alopecia) in adults. It is applied directly to the scalp to help stabilize hair loss.

Q: How long does it take for Alopexy to work?

A: The response to Alopexy is gradual. Treatment typically requires several months of consistent use before a visible effect, such as stabilizing hair loss or promoting some hair regrowth, may be observed. If treatment is stopped, any effects gained are generally reversible, and hair loss may resume.

Q: What happens if I miss a dose of Alopexy?

A: If a dose is missed, it is generally advised not to double the dose to make up for the missed application. The medication should be continued with the next scheduled application. Consistent, regular application is considered important for maintaining the product's effect.

How should Alopexy be stored and disposed of?

How to Store and Dispose of Alopexy (Minoxidil) Solution

Official regulatory guidelines define specific storage and disposal requirements for Alopexy solution to maintain product integrity and safety.

Storage Requirements

Alopexy must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The solution must be kept in its tightly closed container and protected from heat, direct light, and moisture. Due to its composition, the medicine is flammable and must be stored strictly away from fire or flame.

Stability and Child Safety

This medicine must be kept out of the sight and reach of children.

Once the bottle is opened, the solution has a limited shelf life of one month and any remaining product must be discarded after this time.

Disposal Instructions

Unused or expired Alopexy must not be disposed of in household trash or wastewater. To ensure proper environmental protection, consult a pharmacist for instructions on discarding the medicine according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBelgium

flagPoland

flagRomania

flagRussia

flagSpain

flagTunisia

Equivalent of Alopexy found in:

A-Z Index: